Cargando…

Botulinum toxin type A with or without needle electromyographic guidance in patients with cervical dystonia

AIM: To investigate the efficacy and safety of electromyography (EMG)- and palpation-guided botulinum toxin type A injection in cervical dystonia (CD) patients. METHODS: In this randomized, controlled trial, 68 CD patients were randomly allocated to two groups, receiving botulinum toxin type A injec...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Chuanjie, Xue, Fang, Chang, Wansheng, Lian, Yajun, Zheng, Yake, Xie, Nanchang, Zhang, Lu, Chen, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977261/
https://www.ncbi.nlm.nih.gov/pubmed/27547666
http://dx.doi.org/10.1186/s40064-016-2967-x
_version_ 1782446992977297408
author Wu, Chuanjie
Xue, Fang
Chang, Wansheng
Lian, Yajun
Zheng, Yake
Xie, Nanchang
Zhang, Lu
Chen, Chen
author_facet Wu, Chuanjie
Xue, Fang
Chang, Wansheng
Lian, Yajun
Zheng, Yake
Xie, Nanchang
Zhang, Lu
Chen, Chen
author_sort Wu, Chuanjie
collection PubMed
description AIM: To investigate the efficacy and safety of electromyography (EMG)- and palpation-guided botulinum toxin type A injection in cervical dystonia (CD) patients. METHODS: In this randomized, controlled trial, 68 CD patients were randomly allocated to two groups, receiving botulinum toxin type A injections guided by either palpation (Group A) or EMG (Group B). The primary endpoint is defined as the difference in the Tsui score between groups at 16 weeks. The secondary endpoints were the visual analog scale (VAS) and Hospital Anxiety and Depression Scale (HADS) scores and Clinical and Patient Global Impression of Change (CGIC and PGIC). RESULTS: Sixty-five patients completed the study. No significant difference was observed in the Tsui score between groups A and B at 4, 8, and 12 weeks after treatment (p > 0.05). However, 16 weeks after treatment, the Tsui score of group A was significantly higher than that of group B. For both groups, the degree of pain at each time point during follow-up significantly reduced after treatment. However, no significant difference was observed in VAS scores between the two groups. Interestingly, the patient HADS score decreased without statistical significance 8 weeks following treatment. No significant difference in HADS scores was observed between the two groups. Additionally, there was no significant difference in PGIC and CGIC between the two groups. However, CGIC was significantly higher than PGIC. No significant difference in adverse reactions was observed between groups. CD patients treated with EMG guidance experienced a significantly more pain at the injection site but a significantly lower adverse event occurrence rate of dysphagia when compared to CD patients treated with palpation guidance only. CONCLUSIONS: CD patients treated with EMG guidance experienced a prolonged benefit as measured by the Tsui scale when compared to CD patients treated with palpation guidance alone. EMG-guided injection resulted in a lower incidence of dysphagia and higher incidence of discomfort at the injection site than palpation-guided injection.
format Online
Article
Text
id pubmed-4977261
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-49772612016-08-19 Botulinum toxin type A with or without needle electromyographic guidance in patients with cervical dystonia Wu, Chuanjie Xue, Fang Chang, Wansheng Lian, Yajun Zheng, Yake Xie, Nanchang Zhang, Lu Chen, Chen Springerplus Research AIM: To investigate the efficacy and safety of electromyography (EMG)- and palpation-guided botulinum toxin type A injection in cervical dystonia (CD) patients. METHODS: In this randomized, controlled trial, 68 CD patients were randomly allocated to two groups, receiving botulinum toxin type A injections guided by either palpation (Group A) or EMG (Group B). The primary endpoint is defined as the difference in the Tsui score between groups at 16 weeks. The secondary endpoints were the visual analog scale (VAS) and Hospital Anxiety and Depression Scale (HADS) scores and Clinical and Patient Global Impression of Change (CGIC and PGIC). RESULTS: Sixty-five patients completed the study. No significant difference was observed in the Tsui score between groups A and B at 4, 8, and 12 weeks after treatment (p > 0.05). However, 16 weeks after treatment, the Tsui score of group A was significantly higher than that of group B. For both groups, the degree of pain at each time point during follow-up significantly reduced after treatment. However, no significant difference was observed in VAS scores between the two groups. Interestingly, the patient HADS score decreased without statistical significance 8 weeks following treatment. No significant difference in HADS scores was observed between the two groups. Additionally, there was no significant difference in PGIC and CGIC between the two groups. However, CGIC was significantly higher than PGIC. No significant difference in adverse reactions was observed between groups. CD patients treated with EMG guidance experienced a significantly more pain at the injection site but a significantly lower adverse event occurrence rate of dysphagia when compared to CD patients treated with palpation guidance only. CONCLUSIONS: CD patients treated with EMG guidance experienced a prolonged benefit as measured by the Tsui scale when compared to CD patients treated with palpation guidance alone. EMG-guided injection resulted in a lower incidence of dysphagia and higher incidence of discomfort at the injection site than palpation-guided injection. Springer International Publishing 2016-08-08 /pmc/articles/PMC4977261/ /pubmed/27547666 http://dx.doi.org/10.1186/s40064-016-2967-x Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research
Wu, Chuanjie
Xue, Fang
Chang, Wansheng
Lian, Yajun
Zheng, Yake
Xie, Nanchang
Zhang, Lu
Chen, Chen
Botulinum toxin type A with or without needle electromyographic guidance in patients with cervical dystonia
title Botulinum toxin type A with or without needle electromyographic guidance in patients with cervical dystonia
title_full Botulinum toxin type A with or without needle electromyographic guidance in patients with cervical dystonia
title_fullStr Botulinum toxin type A with or without needle electromyographic guidance in patients with cervical dystonia
title_full_unstemmed Botulinum toxin type A with or without needle electromyographic guidance in patients with cervical dystonia
title_short Botulinum toxin type A with or without needle electromyographic guidance in patients with cervical dystonia
title_sort botulinum toxin type a with or without needle electromyographic guidance in patients with cervical dystonia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977261/
https://www.ncbi.nlm.nih.gov/pubmed/27547666
http://dx.doi.org/10.1186/s40064-016-2967-x
work_keys_str_mv AT wuchuanjie botulinumtoxintypeawithorwithoutneedleelectromyographicguidanceinpatientswithcervicaldystonia
AT xuefang botulinumtoxintypeawithorwithoutneedleelectromyographicguidanceinpatientswithcervicaldystonia
AT changwansheng botulinumtoxintypeawithorwithoutneedleelectromyographicguidanceinpatientswithcervicaldystonia
AT lianyajun botulinumtoxintypeawithorwithoutneedleelectromyographicguidanceinpatientswithcervicaldystonia
AT zhengyake botulinumtoxintypeawithorwithoutneedleelectromyographicguidanceinpatientswithcervicaldystonia
AT xienanchang botulinumtoxintypeawithorwithoutneedleelectromyographicguidanceinpatientswithcervicaldystonia
AT zhanglu botulinumtoxintypeawithorwithoutneedleelectromyographicguidanceinpatientswithcervicaldystonia
AT chenchen botulinumtoxintypeawithorwithoutneedleelectromyographicguidanceinpatientswithcervicaldystonia